CURE’s head & neck cancer page is a go-to resource for oncology news and updates in the world of head & neck cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight to the latest treatments and research in head & neck cancer.
December 5th 2023
The Food and Drug Administration gave the green light to a phase 1/2 trial of KSQ-001EX for patients with melanoma, head and neck squamous cell carcinoma and non-small cell lung cancer.
October 30th 2023
Novel Drug-Chemo Combo Significantly Improves Survival in Rare Form of Head and Neck Cancer
June 5th 2021The addition of a novel drug to the chemotherapies gemcitabine and cisplatin significantly improved a survival outcome in patients with a rare form of head and neck cancer, compared with chemotherapy alone.
Oral Sex Timing and Intensity Could Be Risk Factors of Oropharyngeal Cancer
February 24th 2021Patients with oropharyngeal cancer demonstrate higher rates of ever performing, timing, number of partners and intensity in oral sex than matching participants, suggesting an association between behavior and diagnosis.
FDA Approves HPV Vaccine Gardasil 9 for Certain Head and Neck Cancers
June 15th 2020The Food and Drug Administration (FDA) has granted accelerated approval to expand the indication of Gardasil 9 (Human papillomavirus 9-valent vaccine, recombinant), a vaccine for the prevention of HPV, to prevent oropharyngeal and other head and neck cancers caused by certain HPV types.
FDA Approves Keytruda Regimens to Treat Head and Neck Squamous Cell Carcinoma
June 11th 2019The Food and Drug Administration approved Keytruda monotherapy and in combination with chemotherapy for the front-line treatments of patients with metastatic or unresectable recurrent head and neck squamous cell carcinoma.
FDA Grants Priority Review to Frontline Keytruda to Treat Recurrent, Metastatic HNSCC
February 11th 2019The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).